ADXS Advaxis, Inc.

8.68
+0.11  (1%)
Previous Close 8.57
Open 8.61
Price To book 3.21
Market Cap 349.76M
Shares 40,295,000
Volume 312,981
Short Ratio 12.06
Av. Daily Volume 571,424

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
ADXS-HER2
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. Advaxis to Host Investor & Analyst Day on June 12
  2. Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
  3. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : May 15, 2017
  4. Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis
  5. ETFs with exposure to Advaxis, Inc. : May 4, 2017
  6. Advaxis, Inc. – Value Analysis (NASDAQ:ADXS) : April 28, 2017
  7. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : April 27, 2017
  8. Advaxis Recognized as One of New Jersey’s “Best Places to Work 2017”
  9. ETFs with exposure to Advaxis, Inc. : April 21, 2017
  10. Advaxis Appoints Anthony Lombardo as Chief Business Officer
  11. ETFs with exposure to Advaxis, Inc. : March 27, 2017
  12. EMA Certification Paves Way for Advaxis Drug
  13. EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
  14. Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017
  15. Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
  16. Advaxis to Present at the 2017 Barclays Global Healthcare Conference
  17. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017
  18. Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
  19. Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug